FdaApplication
NDA 050790
Identifiers
- fda_app_no: NDA050790
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2002-12-23 |
Revenue by product
RESTASIS
| Period | Revenue |
|---|---|
| Q4 2024 | $114.0M |
| Q3 2024 | $21.0M |
| Q2 2024 | $32.0M |
| Q1 2024 | $57.0M |
| Q4 2023 | $128.0M |
| Q3 2023 | $117.0M |
| Q2 2023 | $99.0M |
| Q1 2023 | $92.0M |
| Q4 2022 | $110.0M |
| Q3 2022 | $142.0M |
| Q2 2022 | $168.0M |
| Q1 2022 | $246.0M |
| Q4 2021 | $364.0M |
| Q3 2021 | $319.0M |
| Q2 2021 | $327.0M |
| Q1 2021 | $280.0M |
| Q4 2020 | $344.0M |
| Q3 2020 | $299.0M |
| Q2 2020 | $144.0M |
| Q1 2020 | $0.0M |
| Q4 2019 | $0.0M |
| Q3 2019 | $0.0M |
| Q2 2019 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| RESTASIS | CYCLOSPORINE | 0.05% | EMULSION;OPHTHALMIC |
| RESTASIS MULTIDOSE | CYCLOSPORINE | 0.05% | EMULSION;OPHTHALMIC |
2 products